Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will present at the 37th Annual Piper Sandler Healthcare Conference on December 2-4, 2025 [1][2] Company Overview - MBX Biosciences utilizes its proprietary PEP™ platform to discover and develop novel peptide therapies [3] - The company has a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism and imapextide (1416) for post-bariatric hypoglycemia, both in Phase 2 development [3] - An obesity portfolio is also in development, including MBX 4291 in Phase 1 and several pre-clinical candidates [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [4] Upcoming Investor Conferences - The company will participate in several investor conferences, including: - Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025, in Boston, MA [2] - Stifel Healthcare Conference on November 12, 2025, in New York, NY [2] - Jefferies Global Healthcare Conference on November 19, 2025, in London, UK [2] - TD Cowen Treatment Advancements in Obesity and Related Disorders Summit on November 24, 2025, virtually [3] Company Pipeline - MBX Biosciences is advancing a pipeline that includes: - Canvuparatide (MBX 2109) for chronic hypoparathyroidism, preparing for Phase 3 development [4] - Imapextide (1416) for post-bariatric hypoglycemia, currently in Phase 2 development [4] - An obesity portfolio including MBX 4291 in Phase 1 development and multiple discovery and pre-clinical candidates [4]

Core Insights - MBX Biosciences, Inc. is participating in the Stifel 2025 Virtual Cardiometabolic Forum, highlighting its focus on precision peptide therapies for endocrine and metabolic disorders [1][2] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company based in Carmel, Indiana, specializing in the discovery and development of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism and imapextide (1416) for post-bariatric hypoglycemia, both in Phase 2 development [3] - Additionally, MBX has an obesity portfolio that includes MBX 4291 in Phase 1 development and multiple discovery and pre-clinical candidates [3]